林箐 副研究员
单位：四川大学华西药学院药剂学系
通讯地址：成都市人民南路三段17号四川大学华西药学院药学大楼605-3室
E-mail: qinglin@scu.edu.cn
教育&工作经历
2009.09–2013.06 四川大学 华西药学院 药学 理学学士
2013.09–2017.06 四川大学 华西药学院 药剂学 理学博士 （3+2+3本硕博连读） 导师：张志荣教授
2017.09–2020.09 四川大学 华西药学院 药剂学系 专职博士后；助理研究员、副研究员（专职科研）
2019.01–2020.01 英国剑桥大学 化学工程与生物技术系 访问研究员 合作教授: Prof. Nigel K.H. Slater FREng
2020.09–至今 四川大学华西药学院药剂学系 副研究员
2021.07–至今 硕士生导师
研究方向
药物递释系统研究
近年承担课题
1. 国家自然科学基金面上项目，82273877，2023.01-2026.12，主持。
2. 国家自然科学基金青年项目，81803447，2019.01-2021.12，主持。
3. 四川省自然科学基金青年项目，23NSFSC3777，2023.01-2024.12，主持。
4. 中国博士后科学基金，2018M633388，2019.01-2022.12，主持。
5. 四川大学博士后交叉学科创新启动基金项目，2019. 01-2020.09，主持。
6. 四川大学专职博士后研发基金，2018SCU12025，2018. 01-2019.12，主持。
近年研究论文
[1] Yu Fu, Wei Liu, Luyao Wang, Biyue Zhu, Mengke Qu, Liuqing Yang, Xun Sun, Tao Gong, Zhi-rong Zhang, Qing Lin*, Ling Zhang*. Erythrocyte-membrane-camouflaged nanoplatform for intravenous glucose-responsive insulin delivery. Advanced Functional Materials, 2018, 28 (41): 1802250.
[2] Kejun Jiang#, Xu Song#, Liuqing Yang, Lin Li, Zhuoya Wan, Xun Sun, Tao Gong, Qing Lin*, Zhirong Zhang*. Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin. Journal of Controlled Release, 2018, 271: 21-30.
[3] Luyao Wang, Mengke Qu, Shiqi Huang, Yu Fu, Liuqing Yang, Shanshan He, Lin Li, Zhirong Zhang, Qing Lin*, Ling Zhang*. A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy. Nanoscale, 2018, 10: 13673-13683.
[4] Xun Hu, Mengdi Jia, Yu Fu, Pei Zhang, Zhirong Zhang, Qing Lin*. A novel low-toxic derivative of celastrol maintains protective effect against acute renal injury. ACS Omega, 2018, 3 (3): 2652-2660.
[5] Bingjie Zhou, Min Li, Xiaomin Xu, Lan Yang, Meiling Ye, Yan Chen, Jiayi Peng, Linyu Xiao, Luyao Wang, Shiqi Huang, Ling Zhang, Qing Lin*, Zhirong Zhang. Integrin α2β1 targeting DGEA-modified liposomal doxorubicin enhances anti-tumor efficacy against breast cancer. Molecular Pharmaceutics, 2021, 18 (7): 2634-2646.
[6] Yu Fu, Leilei Wang, Wei Liu, Lan Yang, Lin Li, Luyao Wang, Xun Sun, Zhirong Zhang, Qing Lin*, Ling Zhang*. OX40L blockade cellular nanovesicles for autoimmune diseases therapy. Journal of Controlled Release, 2021, 337: 557-570.
[7] Qiang Zhang, Yikun Han, Honglin Xiang, Min Li, Lan Yang, Qiang Liu, Yan Zhang, Zhirong Zhang, Qing Lin*, Ling Zhang*. Biopharmaceutical, preclinical pharmacokinetic and pharmaco-dynamic investigations of an orally administered novel 3-nbutylphthalide prodrug for ischemic stroke treatment. European Journal of Pharmaceutical Sciences, 2023, 180: 106308.
[8] Lingling Zhu, Xianzhe Yu, Ting Cao, Hanyu Deng, Xiaojun Tang, Qing Lin*, Qinghua Zhou*. Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis. Acta Pharmaceutica Sinica B, 2023, doi.org/10.1016/j.apsb.2023.03.004.
[9] Xiaodong Qi, Tingyu Zhu, Wenwen Hu, Wanjun Jiang, Jinghui Yang, Qing Lin*, Yong Wang*. Multifunctional polyacrylamide/hydrated salt/MXene phase change hydrogels with high thermal energy storage, photothermal conversion capability and strain sensitivity for personal healthcare. Composites Science and Technology, 2023,234: 109947.
[10] Lingling Zhu, Honglin Gao, Ting Wang, Guixiu Xiao, Chenggong Hu*, Qing Lin*, Qinghua Zhou*. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis. Chinese Medical Journal, 2023, accepted.
[11] Qing Lin, Yu Fu, Jia Li, Mengke Qu, Li Deng, Tao Gong*, Zhirong Zhang*. A (polyvinyl caprolactam-polyvinyl acetate–polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability. European Journal of Pharmaceutical Science, 2015, 79: 44-52.
[12] Qing Lin, Liqin Ling, Ling Guo, Tao Gong, Xun Sun, Zhirong Zhang*. Intestinal absorption characteristics of imperialine: in vitro and in situ assessments. Acta Pharmacologica Sinica, 2015, 36.7: 863-873.
[13] Qing Lin, Mengke Qu, Hirak K. Patra, Shanshan He, Luyao Wang, Xun Hu, Linyu Xiao, Yu Fu, Tao Gong, Qin He, Ling Zhang*, Xun Sun, Zhirong Zhang. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer. Journal of Ethnopharmacology, 2020, 247: 112283.
[14] Qing Lin, Yan Li, Meng-Ke Qu, Xing Liu, Zhi-Rong Zhang, Ling Zhang. Preliminary Investigation on Difference of Protein Compositions Between DC2. 4 Cells and Their Derived Exosomes by nanoLC-MS/MS. Journal of Sichuan University Medical Science, 2020, 51(1): 81-86.
[15] Qing Lin, Mengke Qu, Bingjie Zhou, Hirak K. Patra, Zihan Sun, Qiong Luo, Wenyu Yang, Yongcui Wu, Yu Zhang, Lin Li, Lang Deng, Leilei Wang, Tao Gong, Qin He, Ling Zhang*, Xun Sun, Zhirong Zhang. Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine. Journal of Controlled Release, 2019, 311: 104-116.
Dr. Qing Lin
Research Associate Professor
MSc Supervisor
Department: Dept. Pharmaceutics, West China School of Pharmacy, Sichuan University
Corresponding address: Lab 605-3, West China School of Pharmacy, West China Campus, Sichuan University, No. 17 People’s South Road, Chengdu, 610041, P.R China
E-mail: qinglin@scu.edu.cn
Experience of Education & Research Work
2009.09–2013.06 BSc in Pharmacy, West China School of Pharmacy, Sichuan University
2013.09–2017.06 Ph.D in Pharmaceutics, West China School of Pharmacy, Sichuan University, 3+2+3 successive undergraduate and doctoral program (Hierophant: Prof. Zhirong Zhang)
2017.09–2020.09 Postdoctoral fellow/Research Associate in Dept. Pharmaceutics, West China School of Pharmacy, Sichuan University (Advisor: Prof. Zhirong Zhang)
2019.01–2020.01 Visiting Scientist in Dept. Chem Eng & Biotech, University of Cambridge, UK (Advisor: Prof. Nigel K.H. Slater FREng)
2020.09–till now Research Associate Professor in in Dept. Pharmaceutics, West China School of Pharmacy, Sichuan University
2021.07–till now MSc supervisor
Research Interest
Drug delivery and release platforms
Selected Fundings
1. The General Program of National Natural Science Foundation of China, No. 82273877, 2023.01-2026.12, Recipient
2. National Natural Science Foundation of China for Youth Scholars, No. 81803447, 2019.01-2021.12, Recipient
3. Natural Science Foundation of Sichuan Province for Youth Scholars, No. 23NSFSC3777, 2023.01-2024.12, Recipient
4. China Postdoctoral Science Foundation, No. 2018M633388, 2019.01-2022.12, Recipient
5. Postdoctoral Interdisciplinary Innovation Program of Sichuan University, 2019. 01-2020.09, Recipient
6. Fundamental Research Funds for the Central Universities of China, No. 2018SCU12025, 2018. 01-2019.12, Recipient
Selected Publications
[1] Yu Fu, Wei Liu, Luyao Wang, Biyue Zhu, Mengke Qu, Liuqing Yang, Xun Sun, Tao Gong, Zhi-rong Zhang, Qing Lin*, Ling Zhang*. Erythrocyte-membrane-camouflaged nanoplatform for intravenous glucose-responsive insulin delivery. Advanced Functional Materials, 2018, 28 (41): 1802250.
[2] Kejun Jiang#, Xu Song#, Liuqing Yang, Lin Li, Zhuoya Wan, Xun Sun, Tao Gong, Qing Lin*, Zhirong Zhang*. Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin. Journal of Controlled Release, 2018, 271: 21-30.
[3] Luyao Wang, Mengke Qu, Shiqi Huang, Yu Fu, Liuqing Yang, Shanshan He, Lin Li, Zhirong Zhang, Qing Lin*, Ling Zhang*. A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy. Nanoscale, 2018, 10: 13673-13683.
[4] Xun Hu, Mengdi Jia, Yu Fu, Pei Zhang, Zhirong Zhang, Qing Lin*. A novel low-toxic derivative of celastrol maintains protective effect against acute renal injury. ACS Omega, 2018, 3 (3): 2652-2660.
[5] Bingjie Zhou, Min Li, Xiaomin Xu, Lan Yang, Meiling Ye, Yan Chen, Jiayi Peng, Linyu Xiao, Luyao Wang, Shiqi Huang, Ling Zhang, Qing Lin*, Zhirong Zhang. Integrin α2β1 targeting DGEA-modified liposomal doxorubicin enhances anti-tumor efficacy against breast cancer. Molecular Pharmaceutics, 2021, 18 (7): 2634-2646.
[6] Yu Fu, Leilei Wang, Wei Liu, Lan Yang, Lin Li, Luyao Wang, Xun Sun, Zhirong Zhang, Qing Lin*, Ling Zhang*. OX40L blockade cellular nanovesicles for autoimmune diseases therapy. Journal of Controlled Release, 2021, 337: 557-570.
[7] Qiang Zhang, Yikun Han, Honglin Xiang, Min Li, Lan Yang, Qiang Liu, Yan Zhang, Zhirong Zhang, Qing Lin*, Ling Zhang*. Biopharmaceutical, preclinical pharmacokinetic and pharmaco-dynamic investigations of an orally administered novel 3-nbutylphthalide prodrug for ischemic stroke treatment. European Journal of Pharmaceutical Sciences, 2023, 180: 106308.
[8] Lingling Zhu, Xianzhe Yu, Ting Cao, Hanyu Deng, Xiaojun Tang, Qing Lin*, Qinghua Zhou*. Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis. Acta Pharmaceutica Sinica B, 2023, doi.org/10.1016/j.apsb.2023.03.004.
[9] Xiaodong Qi, Tingyu Zhu, Wenwen Hu, Wanjun Jiang, Jinghui Yang, Qing Lin*, Yong Wang*. Multifunctional polyacrylamide/hydrated salt/MXene phase change hydrogels with high thermal energy storage, photothermal conversion capability and strain sensitivity for personal healthcare. Composites Science and Technology, 2023,234: 109947.
[10] Lingling Zhu, Honglin Gao, Ting Wang, Guixiu Xiao, Chenggong Hu*, Qing Lin*, Qinghua Zhou*. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis. Chinese Medical Journal, 2023, accepted.
[11] Qing Lin, Yu Fu, Jia Li, Mengke Qu, Li Deng, Tao Gong*, Zhirong Zhang*. A (polyvinyl caprolactam-polyvinyl acetate–polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability. European Journal of Pharmaceutical Science, 2015, 79: 44-52.
[12] Qing Lin, Liqin Ling, Ling Guo, Tao Gong, Xun Sun, Zhirong Zhang*. Intestinal absorption characteristics of imperialine: in vitro and in situ assessments. Acta Pharmacologica Sinica, 2015, 36.7: 863-873.
[13] Qing Lin, Mengke Qu, Hirak K. Patra, Shanshan He, Luyao Wang, Xun Hu, Linyu Xiao, Yu Fu, Tao Gong, Qin He, Ling Zhang*, Xun Sun, Zhirong Zhang. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer. Journal of Ethnopharmacology, 2020, 247: 112283.
[14] Qing Lin, Yan Li, Meng-Ke Qu, Xing Liu, Zhi-Rong Zhang, Ling Zhang. Preliminary Investigation on Difference of Protein Compositions Between DC2. 4 Cells and Their Derived Exosomes by nanoLC-MS/MS. Journal of Sichuan University Medical Science, 2020, 51(1): 81-86.
[15] Qing Lin, Mengke Qu, Bingjie Zhou, Hirak K. Patra, Zihan Sun, Qiong Luo, Wenyu Yang, Yongcui Wu, Yu Zhang, Lin Li, Lang Deng, Leilei Wang, Tao Gong, Qin He, Ling Zhang*, Xun Sun, Zhirong Zhang. Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine. Journal of Controlled Release, 2019, 311: 104-116.
